Heart Failure with Reduced Ejection Fraction
📧 Sign up to get email alerts when something new happens for Heart Failure with Reduced Ejection Fraction.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2023-02-02Clinical Trial Update: v4 Study Evaluating the Safety, Tolerability and Preliminary Pharmacokinetics and Pharmacodynamics of MYK-491 [Phase 1, Phase 2]
A completed Phase 1/2 trial evaluating safety, tolerability, pharmacokinetics and pharmacodynamics of MYK-491 in heart failure with reduced …
-
CLINICAL_TRIALS research · 2022-12-09Clinical Trial Update: Cardiometabolic Effects of Dapagliflozin in Heart Failure With Reduced or Mildly Reduced Ejection Fraction [Phase 2]
Phase 2 clinical trial evaluating the cardiometabolic effects of dapagliflozin in heart failure with reduced or mildly reduced ejection frac…
-
FDA approval · 2022-11-21FDA Approved: VERQUVO — Supplemental Application (Merck Sharp & Dohme LLC)
The FDA approved a supplemental application for Verquvo (vericiguat) from Merck Sharp & Dohme LLC, updating the drug’s labeling as part of t…
-
CLINICAL_TRIALS trial_result · 2022-11-03Clinical Trial Update: S086 Tablets for Chronic Heart Failure With Reduced Ejection Fraction [Phase 3]
Phase 3 trial update for S086 tablets in chronic heart failure with reduced ejection fraction (HFrEF) currently recruiting.
-
CLINICAL_TRIALS trial_result · 2022-11-02Clinical Trial Update: " Evaluation of Safety and Efficacy of Empagliflozin and Sacubitril/Valsartan for CHF With Reduced Ejection Fraction in ACHD " [Phase 2, Phase 3]
Clinical trial evaluating safety and efficacy of empagliflozin and sacubitril/valsartan for heart failure with reduced ejection fraction in …
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2022-07-14Clinical Trial Update: Study to Assess the Safety, Tolerability and PK/PD After 4 Weekly SC Injections of PB1046 in Subjects With Stable HFrEF [Phase 2]
Phase 2 trial update evaluating safety, tolerability, and PK/PD after 4 weekly SC injections of PB1046 in subjects with stable heart failure…
-
CLINICAL_TRIALS trial_result · 2022-07-08Clinical Trial Update: A Multicenter Trial of a Shared DECision Support Intervention for Patients Offered Implantable Cardioverter-DEfibrillators [NA]
Clinical trial evaluating a shared decision support intervention for patients offered implantable cardioverter-defibrillators has completed …
-
CLINICAL_TRIALS trial_result · 2022-05-24Clinical Trial Update: Safety and Tolerability of Sacubitril/Valsartan in Heart Failure Patient With Reduced Ejection Fraction [Phase 4]
Phase 4 trial evaluating safety and tolerability of sacubitril/valsartan in patients with Heart Failure with reduced ejection fraction.
-
CLINICAL_TRIALS trial_result · 2022-05-04Clinical Trial Update: Beta 3 Agonist Treatment in Heart Failure-2 [Phase 2, Phase 3]
Phase 2/3 trial update for a beta-3 agonist in heart failure with reduced ejection fraction (NYHA class III–IV) has been completed.
-
CLINICAL_TRIALS research · 2022-04-27Clinical Trial Update: Short-term Effects of Dapagliflozin on Peak VO2 in HFrEF [Phase 4]
Phase 4 trial update evaluating the short-term effects of dapagliflozin on peak VO2 in patients with heart failure with reduced ejection fra…
-
CLINICAL_TRIALS trial_result · 2022-01-05Clinical Trial Update: Effect of Carvedilol Rapid Up-Titration in Patients With Heart Failure With Reduced Ejection Fraction [Phase 4]
A Phase 4 trial update examines the effect of rapid up-titration of carvedilol in patients with heart failure with reduced ejection fraction…
-
FDA approval · 2021-12-30FDA Approved: IVABRADINE — Original Application (Ingenus Pharmaceuticals, LLC)
FDA approved the original ANDA for IVABRADINE, allowing Ingenus Pharmaceuticals, LLC to market a generic form of ivabradine in the United St…
-
CLINICAL_TRIALS trial_result · 2021-12-03Clinical Trial Update: Effects of Ketones and Niacin in Heart Failure Patients [Phase 2]
Phase 2 trial assessing the effects of ketones and niacin in patients with systolic heart failure; study completed.
-
CLINICAL_TRIALS trial_result · 2021-12-01Clinical Trial Update: Dapagliflozin Effect on Symptoms and Biomarkers in Patients With Heart Failure [Phase 4]
Phase 4 trial evaluating the effects of dapagliflozin on symptoms and biomarkers in patients with chronic heart failure with reduced ejectio…
-
CLINICAL_TRIALS trial_result · 2021-10-19Clinical Trial Update: Comparison of Effects of Atorvastatin Versus Rosuvastatin on Cardiac Function in Heart Failure Patients [Phase 4]
Phase 4 trial comparing atorvastatin versus rosuvastatin effects on cardiac function in patients with heart failure with reduced ejection fr…
-
CLINICAL_TRIALS research · 2021-09-17Clinical Trial Update: Electronic Health Record-leveraged, Patient-centered, Intensification of Chronic Care for HF [NA]
Clinical trial update on an electronic health record–driven, patient-centered approach to intensify chronic care for heart failure; results …
-
FDA approval · 2021-08-04FDA Approved: CORLANOR — Supplemental Application (Amgen Inc)
The FDA approved a supplemental application for CORLANOR (ivabradine) from Amgen Inc.
-
CLINICAL_TRIALS trial_result · 2021-08-03Clinical Trial Update: The Effects of SGLTi on Diabetic Cardiomyopathy [Phase 4]
Phase 4 trial update investigating the effects of SGLT inhibitors on diabetic cardiomyopathy in patients with type 2 diabetes and heart fail…
-
CLINICAL_TRIALS withdrawal · 2021-07-30Clinical Trial Update: Omecamtiv Mecarbil Post-trial Access Study [Phase 3]
Post-trial access study for omecamtiv mercabil (Omecamtiv Mecarbil) in chronic heart failure with reduced ejection fraction was withdrawn.
-
CLINICAL_TRIALS trial_result · 2021-07-20Clinical Trial Update: Registrational Study With Omecamtiv Mecarbil (AMG 423) to Treat Chronic Heart Failure With Reduced Ejection Fraction [Phase 3]
Phase 3 registrational study of omecamtiv mecarbil (AMG 423) for chronic heart failure with reduced ejection fraction has completed with pos…
-
CLINICAL_TRIALS trial_result · 2021-06-15Clinical Trial Update: Phase IIb Safety and Efficacy Study of Different Oral Doses of BAY94-8862 in Subjects With Worsening Chronic Heart Failure and Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone [Phase 2]
Phase IIb study evaluating different oral doses of BAY94-8862 in chronic heart failure with left ventricular systolic dysfunction, with or w…
-
CLINICAL_TRIALS trial_result · 2021-05-18Clinical Trial Update: EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Reduced Ejection Fraction (EMPEROR-Reduced) [Phase 3]
Phase 3 trial results for empagliflozin in heart failure with reduced ejection fraction have been completed and results posted.
-
CLINICAL_TRIALS trial_result · 2021-05-05Clinical Trial Update: DETERMINE-reduced - Dapagliflozin Effect on Exercise Capacity Using a 6-minute Walk Test in Patients With Heart Failure With Reduced Ejection Fraction [Phase 3]
Phase 3 trial assessing the effect of dapagliflozin on exercise capacity in heart failure with reduced ejection fraction using a 6-minute wa…
-
CLINICAL_TRIALS trial_result · 2021-04-26Clinical Trial Update: Comparison of Pre- and Post-discharge Initiation of LCZ696 Therapy in HFrEF Patients After an Acute Decompensation Event [Phase 4]
Phase 4 trial evaluating initiation of LCZ696 (sacubitril/valsartan) therapy before vs after hospital discharge in patients with heart failu…
-
CLINICAL_TRIALS trial_result · 2021-03-25Clinical Trial Update: Phase IIb Safety and Efficacy Study of Four Dose Regimens of BAY1021189 in Patients With Heart Failure With Reduced Ejection Fraction Suffering From Worsening Chronic Heart Failure (SOCRATES-REDUCED) [Phase 2]
Phase IIb study evaluating four dose regimens of BAY1021189 in heart failure with reduced ejection fraction (SOCRATES-REDUCED) completed wit…